Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring

Fred Saad, Cora N. Sternberg, Eleni Efstathiou, Karim Fizazi, Katharina Modelska, Xun Lin, Jennifer Sugg, Joyce Steinberg, Bettina Noerby, Neal D. Shore, Maha Hussain

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.

Original languageEnglish (US)
Pages (from-to)847-853
Number of pages7
JournalEuropean urology
Volume78
Issue number6
DOIs
StatePublished - Dec 2020

Keywords

  • Enzalutamide
  • Nonmetastatic castration-resistant prostate cancer
  • Prostate Cancer Working Group 2
  • Prostate-specific antigen progression

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring'. Together they form a unique fingerprint.

Cite this